ATR

Global ATR Protein Inhibitors Market Set to Revolutionize Cancer Treatment and Expand into Neurodegenerative and Infectious Diseases - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, BAY, Alzheimer's disease, AstraZeneca, Cholangiocarcinoma, Genetic testing, Ovarian cancer, Therapy, Parkinson's disease, Breast, Emotional dysregulation, Research, Virus, Clinical trial, Berzosertib, COVID-19, Viral, Ataxia telangiectasia and Rad3 related, Radiation, HIV-1, DNA repair, Vertex Pharmaceuticals, Bone marrow, Cancer, Investment, ATR, Patient, Ataxia–telangiectasia, DNA, Pharmaceutical industry, Vaccine, Bayer, Merck

A promising frontier in cancer pharmaceutical research, the inhibition of Ataxia telangiectasia and Rad3 related kinase (ATR kinase) is poised to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.

Key Points: 
  • A promising frontier in cancer pharmaceutical research, the inhibition of Ataxia telangiectasia and Rad3 related kinase (ATR kinase) is poised to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.
  • Pipeline Analysis: The report offers insights into the global ATR protein inhibitors clinical pipeline, categorized by company, indication, and phase.
  • Development Trends: ATR inhibitors are expanding their scope to include neurodegenerative diseases and viral infections, opening new avenues for treatment.
  • This innovative approach to targeting DNA damage response pathways has the potential to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.

Aptar Named Among Top 15 of the ‘World’s Top Companies for Women 2023’ by Forbes

Retrieved on: 
Wednesday, November 1, 2023
Public Policy, Government, Women, Human Resources, Packaging, Labor, Professional Services, Consumer, Manufacturing, Female, Woman, AptarGroup, Statista, NYSE, Public opinion, Multimedia, Employee resource group, Culture, ATR, Nursing

Aptar is among the top 5% of companies, ranked 13 out of the 400 companies included on the list by Forbes and their partner Statista.

Key Points: 
  • Aptar is among the top 5% of companies, ranked 13 out of the 400 companies included on the list by Forbes and their partner Statista.
  • For this ranking companies were evaluated in three categories including employer brand, public opinion and leadership.
  • We are not only supporting women but providing exposure to new growth opportunities.
  • For a full list of the World’s Top Companies for Women and a breakdown of the methodology, please visit the Forbes website here .

Global Synthetic Fuels Market to Soar to $70.1 Billion by 2030, Driven by Rising Investments and Diversification in Primary Energy Mix - ResearchAndMarkets.com

Retrieved on: 
Monday, October 30, 2023
Alternative Vehicles, Fuels, Automotive Manufacturing, Manufacturing, Automotive, Chemicals, Plastics, Carbon, Synthetic fuel, Ammonia, MEA, MTL, Aerospace, Synthetic, Methanol, Biomass, Compound annual growth rate, GTL, Chemical industry, Coal, Gasoline, Region, Fischer–Tropsch process, Transport, Electric vehicle, Research, Marine, Hydrogen, Project delivery method, Growth, Private sector, High, USD, AGC Aerospace & Defense, SMR, Natural gas, Heat, Natural Resources, PTL, Defense, ATR, Fuel pump, Diesel fuel, Renewable energy, Jet fuel, Chemical substance, Kerosene

The global synthetic fuels market is poised for substantial growth, projected to reach USD 70.1 billion by 2030 from USD 48.4 billion in 2023, reflecting a notable Compound Annual Growth Rate (CAGR) of 5.4%.

Key Points: 
  • The global synthetic fuels market is poised for substantial growth, projected to reach USD 70.1 billion by 2030 from USD 48.4 billion in 2023, reflecting a notable Compound Annual Growth Rate (CAGR) of 5.4%.
  • GTL fuel is versatile and finds applications in transportation, power generation, and heating, offering a cleaner energy option.
  • Synthetic fuels play a pivotal role in the chemical sector, reducing greenhouse gas emissions and dependence on fossil fuels.
  • In terms of applications, the gasoline segment secured the second-largest market share in synthetic fuels in 2022.

Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

Retrieved on: 
Monday, October 30, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, PARP1, PARP, DDR, ATM, ADP, Health care, Research and development, Merck, Exercise, Multimedia, Development, ADC, Partnership, Jiangsu Hengrui Medicine, Cancer, Merck Group, ATR, Patient, DNA, Fine chemical, Pharmaceutical industry

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).

Key Points: 
  • Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).
  • The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167.
  • In addition, Merck KGaA, Darmstadt, Germany, has the option to co-promote both assets in China.
  • All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website.

Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

Retrieved on: 
Monday, October 30, 2023
Health, Science, Pharmaceutical, Research, Oncology, PARP1, PARP, DDR, ATM, ADP, Health care, Research and development, Exercise, Multimedia, Development, ADC, Partnership, Jiangsu Hengrui Medicine, Cancer, ATR, Patient, DNA, Fine chemical, Pharmaceutical industry, Merck

Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).

Key Points: 
  • Merck, a leading science and technology company, today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui).
  • The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167.
  • Hengrui will receive payments for the achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Merck.
  • All Merck press releases are distributed by e-mail at the same time they become available on the Merck website.

Hydrogen Generation Market worth $257.9 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, November 2, 2023
Hydrogen, CHP, Methanol, Shell, Chemical industry, Grandpuits-Bailly-Carrois, ATR, Smithfield General Market, Power, PEM, Physical, GHG, Investment, Shell plc, History, Air Liquide, Alkali, Generation, Heat, SMR, Hybrid, Wind, Edmonton International Airport, Linde plc, Government, Air Products, Surface of general type, POX, Greenhouse, Industrial gas, Coal, Natural gas, Renewable energy, Region, Blue, Refinery, Chemical substance, Transport, Application, Green, Ammonia, Industrial, Mobility

Based on source, the Hydrogen Generation Market has been split into Blue hydrogen, Grey hydrogen and Green hydrogen.

Key Points: 
  • Based on source, the Hydrogen Generation Market has been split into Blue hydrogen, Grey hydrogen and Green hydrogen.
  • The Hydrogen Generation Market for grey hydrogen is anticipated to have the biggest market share over the forecast period.
  • This report segments the Hydrogen Generation Market based on application into six segments: petroleum refinery, ammonia production, methanol production, transportation, power generation and others.
  • The Hydrogen Generation Market in Asia Pacific is primarily fueled by the increasing number of petroleum refineries and usage of hydrogen in these refineries.

Hydrogen Generation Market worth $257.9 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, November 2, 2023
Hydrogen, CHP, Methanol, Shell, Chemical industry, Grandpuits-Bailly-Carrois, ATR, Smithfield General Market, Power, PEM, Physical, GHG, Investment, Shell plc, History, Air Liquide, Alkali, Generation, Heat, SMR, Hybrid, Wind, Edmonton International Airport, Linde plc, Government, Air Products, Surface of general type, POX, Greenhouse, Industrial gas, Coal, Natural gas, Renewable energy, Region, Blue, Refinery, Chemical substance, Transport, Application, Green, Ammonia, Industrial, Mobility

Based on source, the Hydrogen Generation Market has been split into Blue hydrogen, Grey hydrogen and Green hydrogen.

Key Points: 
  • Based on source, the Hydrogen Generation Market has been split into Blue hydrogen, Grey hydrogen and Green hydrogen.
  • The Hydrogen Generation Market for grey hydrogen is anticipated to have the biggest market share over the forecast period.
  • This report segments the Hydrogen Generation Market based on application into six segments: petroleum refinery, ammonia production, methanol production, transportation, power generation and others.
  • The Hydrogen Generation Market in Asia Pacific is primarily fueled by the increasing number of petroleum refineries and usage of hydrogen in these refineries.

Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways

Retrieved on: 
Tuesday, October 24, 2023
Aprea-Cuccaro clan, IND, DDR, APRE, WEE1, MD Anderson Cancer Center, Ataxia–telangiectasia, University of Pennsylvania, News, KOL, Perelman School of Medicine at the University of Pennsylvania, University, Therapy, ATR, Patient, Pharmaceutical industry

DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET.

Key Points: 
  • DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET.
  • The Aprea Therapeutics team will discuss the Phase 1/2a study evaluating its lead program of a highly potent and selective macrocyclic inhibitor of ataxia telangiectasia and Rad3-related (ATR), ATRN-119, in patients with advanced solid tumors having mutations in defined DDR genes.
  • The session will be available for replay on the News and Events portion of the Investor Relations section of the company’s website.
  • To register for the event, please click here .

Artios Presents Positive Initial Phase 1/1b Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023
Irinotecan, Phase II, DDR, ATM, Ovarian cancer, ESMO, MD, Ataxia–telangiectasia, Drug development, Pharmacokinetics, PK, Biology, Cancer, DNA repair, Platinum, University, Safety, European Society for Medical Oncology, ATR, MD Anderson Cancer Center, Patient, Toxicity, DNA, Medical imaging, Pharmaceutical industry, Casting Society of America

CAMBRIDGE, United Kingdom and NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, presented promising monotherapy data from the Phase 1/1b portion of the ongoing Phase 1/2a study (NCT04657068) of its ataxia telangiectasia and Rad-3 related (“ATR”) kinase inhibitor ART0380 in advanced or metastatic solid tumors as part of a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023. ART0380 is a clinically advanced, oral, highly potent, and selective ATR inhibitor with best-in-class potential. The Phase 1/1b portion of the trial presented at ESMO assessed the safety and tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ART0380 monotherapy in patients with advanced or metastatic solid tumors. The patient population was enriched for cancers harboring DNA damage response deficiencies as identified by the Artios DcoDeR platform (n = 49).

Key Points: 
  • ART0380 is a clinically advanced, oral, highly potent, and selective ATR inhibitor with best-in-class potential.
  • The Phase 1/1b portion of the trial presented at ESMO assessed the safety and tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ART0380 monotherapy in patients with advanced or metastatic solid tumors.
  • The patient population was enriched for cancers harboring DNA damage response deficiencies as identified by the Artios DcoDeR platform (n = 49).
  • Our next-generation ATR inhibitor ART0380 has demonstrated highly encouraging molecular and clinical responses as a monotherapy particularly in patients with DDR deficiency and high replication stress alterations.

Asia-Pacific Emerges as a Powerhouse in the Synthetic Fuels Market, Fueled by Private Sector Investments and Sustainable Energy Initiatives

Retrieved on: 
Wednesday, October 25, 2023
Carbon, Synthetic fuel, Ammonia, MEA, MTL, Aerospace, Synthetic, Methanol, Biomass, Compound annual growth rate, GTL, Chemical industry, Coal, Gasoline, Region, Fischer–Tropsch process, Transport, Electric vehicle, Research, Marine, Hydrogen, Project delivery method, Growth, Private sector, High, USD, AGC Aerospace & Defense, SMR, Natural gas, Heat, Natural Resources, PTL, Defense, ATR, Fuel pump, Diesel fuel, Renewable energy, Jet fuel, Chemical substance, Kerosene

GTL fuel is versatile and finds applications in transportation, power generation, and heating, offering a cleaner energy option.

Key Points: 
  • GTL fuel is versatile and finds applications in transportation, power generation, and heating, offering a cleaner energy option.
  • Synthetic fuels play a pivotal role in the chemical sector, reducing greenhouse gas emissions and dependence on fossil fuels.
  • In terms of applications, the gasoline segment secured the second-largest market share in synthetic fuels in 2022.
  • Ongoing research and innovation are pivotal in advancing the synthetic fuels market, propelling its growth and sustainability.